第二代视觉系统仿生眼植入物恢复部分视力的潜力。
The potential of the second sight system bionic eye implant for partial sight restoration.
作者信息
Luo Yvonne Hsu-Lin, Fukushige Eka, Da Cruz Lyndon
机构信息
a Vitreoretinal Research , Moorfields Eye Hospital NHS Foundation Trust , London , UK.
b Institute of Ophthalmology , University College London , London , UK.
出版信息
Expert Rev Med Devices. 2016 Jul;13(7):673-81. doi: 10.1080/17434440.2016.1195257. Epub 2016 Jun 22.
INTRODUCTION
Second Sight System bionic eye implant, a commercially available visual prosthesis developed by Second Sight Medical Products, has been implanted in over 125 patients with outer retinal dystrophies such as retinitis pigmentosa. The system has gained regulatory approval in both the USA and Europe, and aims to restore vision by electrical stimulation of the nerve cells of the inner retina.
AREAS COVERED
In this review, we present the safety profile of this implant from the international clinical trial and discuss the nature and levels of improvement in visual function achieved by patients implanted with the system. Expert commentary: Future developments for the system will be explored following the discussion of the current usefulness of the device, its limitation as and the areas in which further development is necessary.
引言
Second Sight System仿生眼植入物是Second Sight Medical Products公司研发的一款已上市的视觉假体，已被植入125例以上患有视网膜色素变性等外层视网膜营养不良的患者体内。该系统已在美国和欧洲获得监管批准，旨在通过电刺激视网膜内层的神经细胞来恢复视力。
涵盖领域
在本综述中，我们介绍了该植入物在国际临床试验中的安全性概况，并讨论了植入该系统的患者视觉功能改善的性质和程度。专家评论：在讨论该设备当前的实用性、局限性以及需要进一步开发的领域之后，将探索该系统的未来发展。
Zotero 插件